SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Axcella Health Inc. AXLA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Axcella Health Inc. (AXLA) is a Biotechnology company in the Healthcare sector, currently trading at $4.58. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is AXLA = $60 (+1210% upside).

Net income is $81M (loss), growing at -11%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $2M against $4M equity (Debt-to-Equity (D/E) ratio 0.52, moderate). Current ratio is 1.21 (adequate). Debt-to-assets is 11.4%. Total assets: $19M.

Analyst outlook: 6 / 10 analysts rate AXLA as buy (60%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 73/100 (Pass), Income ?/100 (Fail).

$60.00

▲ 1210.04% Upside

Average Price Target

The 12-month price target for Axcella Health Inc. is $60.00.

AXLA SharesGrow Score Overview

50/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 73/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AXLA

AXLA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $60, implying +1210% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

AXLA: +0%/yr revenue is, -11%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet AXLA: Debt-to-Equity (D/E) ratio 0.52 (moderate), Current ratio is 1.21 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AXLA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 6 / 10 analysts rate AXLA as buy (60%). Analyst consensus target is $60 (+1210% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range4.58-4.58

Volume6.78K

Market Cap$12.5M

Beta (1Y)0.58

Share Statistics

EPS (TTM)-37.25

Shares Outstanding$2.17M

IPO Date2019-05-09

Employees11

CEOCraig R. Jalbert CIRA

Financial Highlights & Ratios

EBITDA$-67.01M

Net Income$-81.19M

Operating Income$-72.8M

Total Cash$17.15M

Total Debt$2.16M

Net Debt$-14.99M

Total Assets$18.93M

Price / Earnings (P/E)-0.1

Analyst Forecast

1Y Price Target$60.00

Target High$60.00

Target Low$60.00

Upside+1,210.0%

Rating ConsensusBuy

Analysts Covering10

Buy 60% Hold 30% Sell 10%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Global Market

CurrencyUSD

ISINUS05454B2043

Price Chart

AXLA

Axcella Health Inc. ↗ · NASDAQ Global Market

Healthcare • Biotechnology

People Also View

Nuvation Bio Inc.

CytomX Therapeutics, Inc.

Assembly Biosciences, Inc.

Instil Bio, Inc.

Kezar Life Sciences, Inc.

Magenta Therapeutics, Inc.

Cyclerion Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message